<DOC>
	<DOCNO>NCT00464347</DOCNO>
	<brief_summary>VERTACL investigate whether triple therapy , Avastin® , half fluence verteporfin photodynamic therapy ( PDT ) , triamcinolone acetonide-preservative free ( TAC- PF ) , result improve 12-month vision outcome compare Avastin® alone participants neovascular AMD .</brief_summary>
	<brief_title>TAC-PF , Avastin® Combination With Photodynamic Therapy Treat Age Related Macular Degeneration</brief_title>
	<detailed_description>The VERTACL study multi-center , randomize , Phase II trial investigate whether triple therapy , Avastin® , half fluence verteporfin PDT , TAC- PF , result improve 12-month vision outcome compare Avastin® alone participants neovascular AMD . Participants randomize ( similar flip coin ) 1:1 ratio one two study group : single therapy ( Avastin® ) , triple therapy ( Avastin® , half fluence verteporfin PDT , TAC- PF ) . Participants Avastin® alone arm receive 1.25 mg intravitreal Avastin® , every study visit . Participants triple-therapy arm receive treatment ( Avastin® , half fluence verteporfin PDT , TAC- PF ) baseline . Following baseline , participant triple therapy study arm receive study treatment as-needed ( PRN ) basis protocol-specific re-treatment criterion meet . After randomization , participant return clinic approximately every six week one year study assessment possible re-treatment . Participants return clinic month 24 final study assessment . Study assessment include : visual acuity , optical coherence tomography , fundus photography .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion Criteria Includes : Drusen &gt; 63 mm Choroidal neovascularization fovea ( Predominantly Classic , Minimally Classic , Occult lesion acceptable ) Greatest linear dimension ( GLD ) entire lesion &lt; 5400 µm ( read center confirmation require ) ETDRS best correct visual acuity 20/40 20/320 ( 73 24 letter score ) Total area lesion must &lt; 9 MPS DA 03 intravitreal injection antiVEGF monotherapy within 6 month randomization continue evidence exudative activity confirm FA OCT within 48 week last injection Exclusion Criteria Includes : Oral steroid use within 6 month Prior complication steroid therapy Prior stroke , myocardial infarction , endstage malignancy Study Eye Exclusion Criteria Geographic atrophy fibrosis fovea Fibrosis , hemorrhage , pigment epithelial detachment hypofluorescent lesion obscure 50 % total lesion Prior treatment verteporfin within 12 month IOP &gt; 25 mmHg participant Cosopt Intraocular surgery within 6 week Prior vitrectomy Peribulbar steroid injection within 6 month Poor reaction topical periocular steroid treatment include elevate IOP</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>AMD</keyword>
	<keyword>wet AMD</keyword>
	<keyword>verteporfin PDT</keyword>
	<keyword>Avastin</keyword>
	<keyword>TAC-PF</keyword>
</DOC>